| pubmed-article:6826722 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C1123023 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0010453 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0016030 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C1135918 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0023821 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0221464 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:6826722 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:6826722 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6826722 | pubmed:dateCreated | 1983-4-7 | lld:pubmed |
| pubmed-article:6826722 | pubmed:abstractText | Binding of human high density lipoproteins (HDL, d = 1.063-1.21) to cultured human fibroblasts and human arterial smooth muscle cells was studied using HDL subjected to heparin-agarose affinity chromatography to remove apoprotein (apo) E and B. Saturation curves for binding of apo E-free 125I-HDL showed at least two components: low-affinity nonsaturable binding and high-affinity binding that saturated at approximately 20 micrograms HDL protein/ml. Scatchard analysis of high-affinity binding of apo E-free 125I-HDL to normal fibroblasts yielded plots that were significantly linear, indicative of a single class of binding sites. Saturation curves for binding of both 125I-HDL3 (d = 1.125-1.21) and apo E-free 125I-HDL to low density lipoprotein (LDL) receptor-negative fibroblasts also showed high-affinity binding that yielded linear Scatchard plots. On a total protein basis, HDL2 (d = 1.063-1.10), HDL3 and very high density lipoproteins (VHDL, d = 1.21-1.25) competed as effectively as apo E-free HDL for binding of apo E-free 125I-HDL to normal fibroblasts. Also, HDL2, HDL3, and VHDL competed similarly for binding of 125I-HDL3 to LDL receptor-negative fibroblasts. In contrast, LDL was a weak competitor for HDL binding. These results indicate that both human fibroblasts and arterial smooth muscle cells possess specific high affinity HDL binding sites. As indicated by enhanced LDL binding and degradation and increased sterol synthesis, apo E-free HDL3 promoted cholesterol efflux from fibroblasts. These effects also saturated at HDL3 concentrations of 20 micrograms/ml, suggesting that promotion of cholesterol efflux by HDL is mediated by binding to the high-affinity cell surface sites. | lld:pubmed |
| pubmed-article:6826722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6826722 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6826722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6826722 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6826722 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:6826722 | pubmed:issn | 0021-9738 | lld:pubmed |
| pubmed-article:6826722 | pubmed:author | pubmed-author:BiermanE LEL | lld:pubmed |
| pubmed-article:6826722 | pubmed:author | pubmed-author:AlberiJ TJT | lld:pubmed |
| pubmed-article:6826722 | pubmed:author | pubmed-author:OramJ FJF | lld:pubmed |
| pubmed-article:6826722 | pubmed:author | pubmed-author:BiesbroeckRR | lld:pubmed |
| pubmed-article:6826722 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6826722 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:6826722 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6826722 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6826722 | pubmed:pagination | 525-39 | lld:pubmed |
| pubmed-article:6826722 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:meshHeading | pubmed-meshheading:6826722-... | lld:pubmed |
| pubmed-article:6826722 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6826722 | pubmed:articleTitle | Specific high-affinity binding of high density lipoproteins to cultured human skin fibroblasts and arterial smooth muscle cells. | lld:pubmed |
| pubmed-article:6826722 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6826722 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:6826722 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6826722 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6826722 | lld:pubmed |
